Find uplifting stories about heroes, innovations, and solutions
8 results for "glioblastoma"
Patients with glioblastoma, the most aggressive form of brain cancer, finally have new hope. Boston researchers just proved a genetically modified virus can extend survival by helping the immune system attack tumors.
Scientists used a genetically modified herpes virus to help immune cells attack glioblastoma, the deadliest brain tumor. Patients in the trial lived longer than expected, offering new hope after 20 years without treatment advances.
Researchers at Brown University Health have discovered a molecule that could revolutionize treatment for glioblastoma, one of the deadliest brain cancers. The breakthrough explains why some tumor cells resist chemotherapy while others don't.
Becca Valle was given months to live after a glioblastoma diagnosis, but a breakthrough ultrasound treatment helped her become part of a rare 10% who survive past five years. The experimental therapy could transform how doctors treat deadly brain cancers.
Scientists at the University of Virginia have discovered a pill that stops glioblastoma, the deadliest brain cancer, from spreading in lab mice without harmful side effects. The breakthrough targets a gene that drives the cancer's aggressive spread through the brain.
A startup is bringing hope to glioblastoma patients with an experimental CAR-T therapy that made all three initial patients' tumors shrink dramatically. One patient remains cancer-free more than 2.5 years after treatment.
Scientists at UCLA built miniature 3D brain models that reveal why the deadliest brain cancer resists treatment, opening doors to personalized therapies. These lab-grown organoids mimic real human brains, showing for the first time how tumors communicate with healthy cells to become more aggressive.
Scientists at McMaster University discovered how deadly glioblastoma grows and identified an existing HIV medication that could fight it. The breakthrough could fast-track treatment for patients who currently have few options.